journal
Journals Cancer Chemotherapy and Pharma...

Cancer Chemotherapy and Pharmacology

https://read.qxmd.com/read/38824270/znf384-transcriptionally-activated-mgst1-to-confer-tmz-resistance-of-glioma-cells-by-negatively-regulating-ferroptosis
#1
JOURNAL ARTICLE
Tengfeng Yan, Ping Hu, Shigang Lv, Minhua Ye, Miaojing Wu, Hua Fang, Bing Xiao
BACKGROUND: Drug resistance is one of the major reasons of the poor prognosis and recurs frequently in glioma. Ferroptosis is considered to be a new therapeutic strategy for glioma. METHODS: Microsomal glutathione S-transferase 1 (MGST1) expression in glioma samples was ensured through GAPIA database, qRT-PCR, western blotting assay and immunohistochemistry. The interaction between zinc finger protein 384 (ZNF384) and MGST1 promoter was analyzed through UCSC and JASPAR databases and further verified by ChIP and luciferase reporter assay...
June 1, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38814343/pre-treatment-amino-acids-and-risk-of-paclitaxel-induced-peripheral-neuropathy-in-swog-s0221
#2
JOURNAL ARTICLE
Ciao-Sin Chen, Gary Zirpoli, G Thomas Budd, William E Barlow, Lajos Pusztai, Gabriel N Hortobagyi, Kathy S Albain, Andrew K Godwin, Alastair Thompson, N Lynn Henry, Christine B Ambrosone, Kathleen A Stringer, Daniel L Hertz
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting and debilitating neurotoxicity of many commonly used anti-cancer agents, including paclitaxel. The objective of this study was to confirm the previously found inverse association between pre-treatment blood concentrations of histidine and CIPN occurrence and examine relationships of other amino acids with CIPN severity. METHODS: Pre-treatment serum concentrations of 20 amino acids were measured in the SWOG S0221 (NCT00070564) trial of patients with early-stage breast cancer receiving paclitaxel...
May 30, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38814342/oral-docetaxel-plus-encequidar-a-phase-1-clinical-trial
#3
LETTER
David Wang, Noelyn Hung, Tak Hung, Karen Eden, Wing-Kai Chan, Rudolf Kwan, Albert Qin, Cynthia Chang, Stephen Duffull, Paul Glue, Christopher Jackson
PURPOSE: To determine the bioavailability, safety, and tolerability of a single dose of oral docetaxel plus encequidar (oDox + E) and compare its pharmacokinetic exposure with current standard of care IV docetaxel. INTRODUCTION: Docetaxel is a taxane widely used as an anti-neoplastic agent. Due to low oral bioavailability secondary to gut P-glycoprotein (P-gp) efflux, its current use is limited to intravenous administration. Oral docetaxel may provide a less resource intensive, more convenient, and tolerable alternative...
May 30, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38782791/physiologically-based-pharmacokinetic-models-versus-allometric-scaling-for-prediction-of-tyrosine-kinase-inhibitor-exposure-from-adults-to-children
#4
JOURNAL ARTICLE
Maddalena Centanni, Omar Zaher, David Elhad, Mats O Karlsson, Lena E Friberg
PURPOSE: Model-based methods can predict pediatric exposure and support initial dose selection. The aim of this study was to evaluate the performance of allometric scaling of population pharmacokinetic (popPK) versus physiologically based pharmacokinetic (PBPK) models in predicting the exposure of tyrosine kinase inhibitors (TKIs) for pediatric patients (≥ 2 years), based on adult data. The drugs imatinib, sunitinib and pazopanib were selected as case studies due to their complex PK profiles including high inter-patient variability, active metabolites, time-varying clearances and non-linear absorption...
May 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38782790/overexposure-to-venetoclax-is-associated-with-prolonged-duration-of-neutropenia-during-venetoclax-and-azacitidine-therapy-in-japanese-patients-with-acute-myeloid-leukemia
#5
JOURNAL ARTICLE
Takahiro Kobayashi, Honami Sato, Masatomo Miura, Yayoi Fukushi, Wataru Kuroki, Fumiko Ito, Kazuaki Teshima, Atsushi Watanabe, Naohito Fujishima, Isuzu Kobayashi, Yoshihiro Kameoka, Naoto Takahashi
PURPOSE: An observational study was conducted to evaluate the pharmacokinetics of venetoclax and its impact on the efficacy and safety for Japanese patients with acute myeloid leukemia (AML) treated with venetoclax and azacitidine therapy. METHODS: The association between the plasma concentration, after the first cycle of azacitidine and venetoclax therapy, and the efficacy and safety was evaluated in 33 patients with untreated or relapsed/refractory AML. RESULTS: Full dose of venetoclax was administered to all patients...
May 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38743253/non-linear-iv-pharmacokinetics-of-the-atr-inhibitor-berzosertib-m6620-in-mice
#6
JOURNAL ARTICLE
Joshua J Deppas, Brian F Kiesel, Jianxia Guo, Robert A Parise, D Andy Clump, David Z D'Argenio, Christopher J Bakkenist, Jan H Beumer
BACKGROUND: The Ataxia Telangiectasia and Rad3-related (ATR) protein complex is an apical initiator of DNA damage response pathways. Several ATR inhibitors (ATRi) are in clinical development including berzosertib (formerly M6620, VX-970). Although clinical studies have examined plasma pharmacokinetics (PK) in humans, little is known regarding dose/exposure relationships and tissue distribution. To understand these concepts, we extensively characterized the PK of berzosertib in mouse plasma and tissues...
May 14, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38734836/using-maximum-plasma-concentration-c-max-to-personalize-taxane-treatment-and-reduce-toxicity
#7
REVIEW
Yuchen Sun, Yue Cheng, Daniel L Hertz
Taxanes are a widely used class of anticancer agents that play a vital role in the treatment of a variety of cancers. However, toxicity remains a major concern of using taxane drugs as some toxicities are highly prevalent, they can not only adversely affect patient prognosis but also compromise the overall treatment plan. Among all kinds of factors that associated with taxane toxicity, taxane exposure has been extensively studied, with different pharmacokinetic (PK) parameters being used as toxicity predictors...
May 11, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38714534/combined-treatment-of-all-trans-retinoic-acid-with-tamoxifen-suppresses-ovarian-cancer
#8
JOURNAL ARTICLE
Rui Xu, Xiaowen Yang, Bin Tang, Yifan Mao, Feiyun Jiang
BACKGROUND: Ovarian cancer is a malignant tumor of the female reproductive system, and its mortality rate is as high as 70%. Estrogen receptor α (ERα)-positive ovarian cancer accounted for most of all ovarian cancer patients. ERα can promote the growth and proliferation of tumors. METHODS: The combined effect of All-trans retinoic acid (ATRA) and tamoxifen was obtained by the combination screening of tamoxifen and compound library by MTS. In addition, colony formation assay, flow cytometry analysis, immunofluorescence staining, quantitative real-time polymerase chain reaction (PCR), western blot, and tumor xenotransplantation models were used to further evaluate the efficacy of tamoxifen and ATRA in vitro and in vivo for ER-α-positive ovarian cancer...
May 7, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38703321/effect-of-food-on-the-pharmacokinetics-and-safety-profiles-of-a-new-parp-inhibitor-fuzuloparib-capsules-in-healthy-volunteers
#9
JOURNAL ARTICLE
Pengfei Du, Yao Long, Minhui Wang, Yunzhe Huang, Yaqin Wang, Xinyan Chen, Yuhong Lin, Jianbang Wu, Jie Shen, Yuanwei Jia
PURPOSE: This study assessed effect of food on pharmacokinetics (PK) and safety of fuzuloparib capsules. METHODS: A randomized, open-label, two-cycle, two-sequence, crossover clinical trial was conducted. 20 subjects were randomly assigned to 2 groups at a 1:1 ratio. The first group subjects were orally administered 150 mg fuzuloparib capsules under fasting condition in first dosing cycle. The same dose of fuzuloparib capsules were taken under postprandial state after a 7-day washout period...
May 4, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38678150/gene-polymorphisms-of-tacr1-serve-as-the-potential-pharmacogenetic-predictors-of-response-to-the-neurokinin-1-receptor-antagonist-based-antiemetic-regimens-a-candidate-gene-association-study-in-breast-cancer-patients
#10
JOURNAL ARTICLE
Marziyeh Ghorbani, Soha Namazi, Mehdi Dehghani, Farideh Razi, Bahman Khalvati, Ali Dehshahri
PURPOSE: The current candidate gene association study aims to investigate tag SNPs from the TACR1 gene as pharmacogenetic predictors of response to the antiemetic guidelines-recommended, NK-1 receptor antagonist-based, triple antiemetic regimens. METHODS: A set of eighteen tag SNPs of TACR1 were genotyped in breast cancer patients receiving anthracycline and cyclophosphamide (with/without docetaxel) applying real-time PCR-HRMA. Data analysis for 121 ultimately enrolled patients was initiated by defining haplotype blocks using PHASE v...
April 27, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38652271/exploring-the-effect-of-brca1-2-status-on-chemotherapy-induced-hematologic-toxicity-in-patients-with-ovarian-cancer
#11
JOURNAL ARTICLE
In Hee Lee, Soo Jung Lee, Juhyung Kim, Yoon Hee Lee, Gun Oh Chong, Jong Mi Kim, Juhun Lee, Nan Young Lee, Seo Young Park, Dea Gy Hong, Yee Soo Chae
OBJECTIVE: BRCA1/2 are integral to the DNA repair mechanism and their germline pathogenic variants (gBRCA) result in a high risk for developing breast and ovarian cancer. Patients with gBRCA mutations showed increased sensitivity to DNA cross-linking agent but might have increased treatment-related toxicities. Thus, we hypothesized that gBRCA mutation ovarian cancer patients who underwent platinum-based chemotherapy might be at higher risk of developing chemotherapy-induced hematologic toxicity...
April 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38643311/pharmacokinetic-study-of-capivasertib-and-the-cyp3a4-substrate-midazolam-in-patients-with-advanced-solid-tumors
#12
JOURNAL ARTICLE
Claire Miller, Roberto Sommavilla, Cindy L O'Bryant, Minal Barve, Afshin Dowlati, Jason J Luke, Mahmuda Khatun, Thomas Morris, Marie Cullberg
PURPOSE: Capivasertib, a potent, selective inhibitor of all three AKT serine/threonine kinase (AKT) isoforms, is being evaluated in phase 3 trials in advanced breast and prostate cancer. This study evaluated the drug-drug interaction risk of capivasertib with the cytochrome P450 3A substrate midazolam in previously treated adults with advanced solid tumors. METHODS: Patients received oral capivasertib 400 mg twice daily (BID) on an intermittent schedule (4 days on/3 days off) starting on day 2 of cycle 1 (29 days) and on day 1 of each 28-day cycle thereafter...
April 20, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38642149/preventive-effect-of-free-radical-scavenger-edaravone-lotion-on-cyclophosphamide-chemotherapy-induced-alopecia
#13
JOURNAL ARTICLE
Takumi Tsuji, Katsuaki Yoneda, Yu Igawa, Erika Minamino, Nodoka Otani, Yuya Yoshida, Takeyuki Kohno
PURPOSE: We investigated the inhibitory effect of edaravone (EDR) lotion on chemotherapy-induced alopecia (CIA) to improve the quality of life for patients with cancer. METHODS: Wistar rats were intraperitoneally injected with cyclophosphamide (CPA, 75 mg/kg) to induce CIA and divided into six groups: (1) Control; (2) EDR 0%; (3) EDR 0.3%; (4) EDR 3%. The TUNEL-positive area was examined histologically, and mRNA expression levels of the apoptosis-related factors, such as B-cell/CLL lymphoma 2 (Bcl-2), and Bcl-2-associated X protein (Bax), were determined...
April 20, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38609654/parp1-promotes-egfr-tki-drug-resistance-via-pi3k-akt-pathway-in-non-small-cell-lung-cancer
#14
JOURNAL ARTICLE
Xianping Xu, Yu Liu, Qiang Gong, Le Ma, Wei Wei, Linqiong Zhao, Zhibin Luo
PURPOSE: Tyrosine kinase inhibitor (TKI) resistance is the main type of drug resistance in lung cancer patients with epidermal growth factor receptor (EGFR) mutations, but its underlying mechanism remains unclear. The purpose of this work was to investigate the mechanism by which PARP1 regulates EGFR-TKI resistance to identify potential targets for combating drug resistance. METHODS: The GEO databases, TCGA databases, western blot and qPCR studies were used to investigate the expression of PARP1 in lung cancer cells and tissues and its correlation with the prognosis of lung cancer...
April 12, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38584202/prognostic-impact-of-concomitant-ph-regulating-drugs-in-patients-with-non-small-cell-lung-cancer-receiving-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-the-tokushukai-real-world-data-project-01-s1
#15
JOURNAL ARTICLE
Kiyoaki Uryu, Yoshinori Imamura, Rai Shimoyama, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Otani, Makoto Hibino, Shigeto Horiuchi, Tomoya Fukui, Ryuta Fukai, Yusuke Chihara, Akihiko Iwase, Noriko Yamada, Yukihiro Tamura, Hiromasa Harada, Nobuaki Shinozaki, Toyoshi Shimada, Asuka Tsuya, Masahiro Fukuoka, Hironobu Minami
PURPOSE: This study aimed to examine the prognostic impact of concomitant pH-regulating drug use in patients with epidermal growth factor receptor (EGFR)-mutation-positive non-small-cell lung cancer (NSCLC) receiving EGFR-tyrosine kinase inhibitors (TKIs). METHODS: We conducted a nationwide retrospective cohort study and reviewed clinical data of consecutive patients with NSCLC treated with the first-line EGFR-TKIs in 46 hospitals between April 2010 and March 2020...
April 8, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38556530/correction-to-phase-i-study-of-the-anti%C3%A2-tigit-antibody-tiragolumab-in-combination-with-atezolizumab-in-japanese-patients-with-advanced-or-metastatic-solid-tumors
#16
Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, Shoyo Shibata, Toshio Shimizu
No abstract text is available yet for this article.
March 31, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38536443/a-polo-like-kinase-1-inhibitor-enhances-erastin-sensitivity-in-head-and-neck-squamous-cell-carcinoma-cells-in-vitro
#17
JOURNAL ARTICLE
Xiangping Wu, Jing Wu
BACKGROUND: Polo-like kinase 1 (PLK1) is a critical therapeutic target in the treatment of head and neck squamous cell carcinoma (HNSCC). The objective of this study was to investigate the therapeutic effect of the combination of BI 2536, a PLK1 inhibitor, and erastin, a ferroptosis inducer, in HNSCC. METHODS: The proliferation, invasion, and migration abilities of Tu177 and FaDu cells upon exposure to BI 2536 and erastin, used in combination or alone, were tested...
March 27, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38530444/correction-to-inhibition-of-proteinase-activated-receptor-2-par2-decreased-the-malignant-progression-of-lung-cancer-cells-and-increased-the-sensitivity-to-chemotherapy
#18
Hongjie Huo, Yu Feng, Qiong Tang
No abstract text is available yet for this article.
March 26, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38520557/postoperative-chemotherapy-relative-dose-intensity-and-overall-survival-in-patients-with-colon-cancer
#19
JOURNAL ARTICLE
Justin C Brown, Jeffrey A Meyerhardt, Shengping Yang, Bette J Caan
PURPOSE: Quantifying the association of chemotherapy relative dose intensity (RDI) with overall survival may enable supportive care interventions that improve chemotherapy RDI to estimate their magnitude of potential clinical benefit. METHODS: This cohort study included 533 patients with stage II-III colon cancer who initiated a planned regimen of 12 cycles of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. The primary exposure was chemotherapy RDI...
March 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38520556/pharmacology-and-pharmacokinetics-of-tazemetostat
#20
JOURNAL ARTICLE
Marco Orleni, Jan H Beumer
Tazemetostat, a novel oral selective inhibitor of enhancer of zeste homolog 2 (EZH2), was approved by the Food and Drug Administration (FDA) in 2020 for use in patients with advanced epithelioid sarcoma or relapsed/refractory (R/R) EZH2-mutated follicular lymphoma. These indications were approved by the FDA trough accelerated approval based on objective response rate and duration of response that resulted from phase 2 clinical trials. Tazemetostat competes with S-adenosylmethionine (SAM) cofactor to inhibit EZH2, reducing the levels of trimethylated lysine 27 of histone 3 (H3K27me3), considered as pharmacodynamic marker...
March 23, 2024: Cancer Chemotherapy and Pharmacology
journal
journal
27426
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.